Iron-doped
apatite nanoparticles (IDANPs) are useful for the prevention, treatment, or alleviation of signs or symptoms associated with viral activation or infection. IDANPs have demonstrated a significant influence over
herpes simplex virus 1 (HSV-1) infection of two
mammalian cell lines. Specifically, IDANPs decreased HSV-1 infection of
African Green Monkey kidney epithelial (Vero) cells by 84% and HSV-1 infection of
human lung bronchus (BEAS-2B) cells by 71%. IDANPs consist of hydroxyapatite (HA) doped with iron. HA is a mineral known to be biocompatible and analogous to the inorganic constituent of mammalian bone and teeth and has been approved by the
Food and Drug Administration (FDA) for many applications in
medicine and
dentistry.
Lactate Dehydrogenase (LDH) and XTT (2,3-Bis 2-methoxy-4-nitro-5-sulfophenyl-2H-tetrazolium-5-carboxanilide inner salt)
cytotoxicity assays revealed that IDANPs are largely non-toxic to Vero, BEAS-2B, and human
cervical cancer (
HeLa) cells lines. HSV-1 afflicted individuals in the United States have been estimated as high as ⅔ the
population. Because IDANPs dramatically decrease HSV-1 infection and are largely non-toxic, their application as an antiviral agent is evident. Further, although iron(III) alone has been shown to diminish replication of deoxyribonucleic acid (
DNA)- and ribonucleic acid (
RNA)-containing viruses, IDANP
cytotoxicity studies indicate that encasement and delivery of iron within an
apatite unit
cell structure diminishes significantly, and in some cases eliminates,
cytotoxicity posed by the introduction of iron(III) alone.